Skip to content
OpenCapital
Get started

Gilead Sciences GILD Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Precigen logo
PrecigenPGEN
-$44.09M-160%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.94M-142%
Sutro Biopharma logo
Sutro BiopharmaSTRO
-$42.26M+37.8%
Incyte logo
IncyteINCY
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%

Valuation

See full
Market cap$153.76B+13.9%
Enterprise value$168.3B+10.7%
P/E16.7×-5.9×
P/S5.2×+0.5×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Calculated from Gilead Sciences’s reported figures.

$2.5Bnet cash from operating−$117.0Mcapital expenditures=$2.43B

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's free cash flow?
Gilead Sciences (GILD) reported free cash flow of $2.43B in Q1 2026.
How has Gilead Sciences's free cash flow changed year-over-year?
Gilead Sciences's free cash flow increased by 46.8% year-over-year, from $1.65B to $2.43B.
What is the long-term trend for Gilead Sciences's free cash flow?
Over 4 years (2021 to 2025), Gilead Sciences's free cash flow has grown at a -3.3% compound annual growth rate (CAGR), from $10.81B to $9.46B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.